Oncology Central

How can we manage resistance to antiangiogenic drugs?

0

The scope of the problem: defining resistance to angiogenesis inhibitors

Angiogenesis is well recognized as an important process in tumor growth and progression. It can be an extremely complex process, although the preponderance of drivers and mediators permits opportunities in drug development to inhibit this process. Key signaling molecules in angiogenesis include the VEGF, FGF2, angiopoietins 1 and 2, HGF and ephrin [1]. The prototypical example of an angiogenesis inhibitor in routine clinical use is bevacizumab, a first-generation recombinant humanized monoclonal antibody against VEGF-A [1].

To view restricted content, please:
Share:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.